Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jul 26;54(7):5097-102.
doi: 10.1167/iovs.13-12157.

SIRT1 promotes RGC survival and delays loss of function following optic nerve crush

Affiliations
Comparative Study

SIRT1 promotes RGC survival and delays loss of function following optic nerve crush

Ling Zuo et al. Invest Ophthalmol Vis Sci. .

Abstract

Purpose: Activation of SIRT1 deacetylase prevents retinal ganglion cell (RGC) loss in experimental optic neuritis, an inflammatory optic neuropathy. While mechanisms of this effect are not known, evidence suggests it involves reduction of oxidative stress. We hypothesized that SIRT1 reduces RGC loss due to oxidative stress in noninflammatory optic neuropathies, and examined effects following traumatic injury.

Methods: Optic nerve crush injury was induced in wild-type C57BL/6 mice, mice overexpressing SIRT1, and mice with conditional deletion of SIRT1 in neurons. Wild-type mice were treated daily with vehicle or 250 mg/kg resveratrol, a naturally occurring polyphenol that activates SIRT1. RGC function was assessed by pupillometry and optokinetic responses (OKR), and RGC survival was measured. Superoxide levels were measured to assess oxidative stress.

Results: Significant decreases in pupillary light responses, OKR and RGC survival occurred 1 week after optic nerve crush, with progressive worsening at 2 to 4 weeks. Resveratrol treatment and SIRT1 overexpression delayed RGC loss and loss of pupillary light responses following optic nerve crush, although no change in RGC loss occurred in neuronal SIRT1-deficient mice. A significant accumulation of superoxide was detected in wild-type optic nerves following crush, and was reduced in mice overexpressing SIRT1 or treated with resveratrol.

Conclusions: SIRT1 delays RGC loss following traumatic injury. Effects are associated with reduced oxidative stress. Results suggest SIRT1-activating drugs may have a specific role in preventing traumatic optic nerve damage, and suggest a broader role for this strategy in treating a variety of optic neuropathies that may include a component of oxidative stress.

Keywords: SIRT1; neuroprotection; oxidative stress; resveratrol; retinal ganglion cells; traumatic optic neuropathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Resveratrol reduces RGC loss after optic nerve crush. The number of Fluorogold-labeled RGCs were counted in 12 standardized fields of whole-mounted retinas from control eyes (total area of 0.74 mm2/retina), and from eyes that underwent optic nerve crush in mice treated daily by oral gavage with 250 mg/kg resveratrol or with vehicle alone. Two weeks post–optic nerve crush, significant RGC loss occurred in vehicle-treated mice as compared with control eyes (***P < 0.001), and resveratrol treatment lead to significantly higher RGC numbers (**P < 0.01). Four weeks post–optic nerve crush, RGC numbers were further reduced, with significant loss compared with controls in both vehicle- and resveratrol-treated mice (***P < 0.001), but RGC survival remained significantly higher in resveratrol-treated versus vehicle-treated optic nerve crush eyes (P < 0.05). Data represent mean ± SEM.
Figure 2
Figure 2
SIRT1-KI and SIRT1-KO mice have altered SIRT1 expression in retina. (A) Western blot of protein extracts from retinas of SIRT1-KI mice and wild-type littermates. Blots of three representative eyes are shown. (B) SIRT1 expression, normalized as a ratio to β–actin levels, is significantly increased in SIRT1-KI retina (***P < 0.001). (C) Western blot of protein extracts from retinas of homozygous SIRT1-KO mice and wild-type littermates. Blots of three representative eyes are shown. (D) SIRT1 expression, normalized as a ratio to β–actin levels, is significantly decreased in SIRT1-KO retina (*P < 0.05).
Figure 3
Figure 3
SIRT1 overexpression prevents RGC loss. (A) Mean ± SEM number of RGCs is significantly decreased 1 week post–optic nerve crush as compared with control eyes (**P < 0.01). No loss of RGCs compared with controls occurs 1 week post–optic nerve crush in SIRT1-KI mice, with RGCs numbers significantly higher than eyes from wild-type (**P < 0.01); heterozygous SIRT1-KO (**P < 0.01); or homozygous SIRT1-KO (*P < 0.05) mouse eyes that underwent optic nerve crush. There is no difference in RGC numbers between wild-type and SIRT1-KO optic nerve crush eyes. Daily treatment with 250 mg/kg resveratrol (RSV) failed to prevent RGC loss following optic nerve crush in homozygous SIRT1-KO mice, with RGC numbers decreased compared with controls (**P < 0.01). (B) Two weeks post–optic nerve crush, the number of RGCs is significantly decreased as compared with control eyes (***P < 0.001). No loss of RGCs compared with controls occurs post–optic nerve crush in SIRT1-KI mice, with RGC numbers significantly higher than eyes from wild-type, heterozygous SIRT1-KO, or homozygous SIRT1-KO (**P < 0.01) mouse eyes that underwent optic nerve crush. There is no difference in RGC numbers between wild-type and SIRT1-KO optic nerve crush eyes. (C) Four weeks post–optic nerve crush, RGC numbers are significantly decreased compared with control eyes (***P < 0.001) and with SIRT1-KI optic nerve crush eyes (*P < 0.05).
Figure 4
Figure 4
Resveratrol and SIRT1 overexpression attenuate loss of RGC function following optic nerve crush. (A) Pupillometry showed a trend toward decreased pupillary constriction 1 week post–optic nerve crush, with significant decreases compared with control eyes at 2 weeks (**P < 0.01) and 4 weeks (***P < 0.001) post–optic nerve crush. SIRT1 overexpression prevented this decrease in pupillary light responses at 2 (*P < 0.05) and 4 (**P < 0.01) weeks; and daily oral resveratrol treatment similarly prevented decreased pupillary responses at 2 (*P < 0.05) and 4 (*P < 0.05) weeks post–optic nerve crush. In SIRT1-KO mice, pupillary light responses decreased 1 and 2 weeks post–optic nerve crush similar to wild-type optic nerve crush eyes. (B) OKR demonstrates a trend toward decreased function 1 and 2 weeks post–optic nerve crush, with or without SIRT1 overexpression, neuronal SIRT1 deletion, or resveratrol treatment. By 4 weeks post–optic nerve crush, significantly decreased OKR responses were detected in vehicle- and resveratrol-treated mice (*P < 0.05). At all time points, SIRT KI and resveratrol-treated mice showed just a trend toward better OKR responses than vehicle-treated mice.
Figure 5
Figure 5
Resveratrol and SIRT1 overexpression prevent accumulation of superoxide in optic nerves. The ROS superoxide was detected by MitoSOX Red staining of optic nerve cross-sections. Representative sections from (A) control, (B) vehicle-treated optic nerve crush, (C) SIRT1-KI, and (D) resveratrol-treated mouse eyes demonstrate high levels of staining following optic nerve crush that is reduced by SIRT1 overexpression and resveratrol treatment. (E) Quantification of the intensity of staining demonstrates significantly higher ROS levels in vehicle-treated optic nerve crush eyes compared with control and with resveratrol-treated and SIRT1-KI optic nerve crush eyes (**P < 0.01). A trend toward increased ROS staining in resveratrol-treated and SIRT1-KI optic nerve crush eyes compared with controls was not significant.

Similar articles

Cited by

References

    1. Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci. 2005; 26: 94–103 - PubMed
    1. Pallàs M, Casadesús G, Smith MA. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr Neurovasc Res. 2009; 6: 70–81 - PubMed
    1. Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2007; 48: 3602–3609 - PMC - PubMed
    1. Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 2010; 30: 328–339 - PMC - PubMed
    1. Fonseca-Kelly Z, Nassrallah M, Uribe J, et al. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol. 2012; 3: 84 - PMC - PubMed

Publication types